{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:24:21Z","timestamp":1790515461598,"version":"4.1.0"},"reference-count":109,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2010,9,8]],"date-time":"2010-09-08T00:00:00Z","timestamp":1283904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:p>\n                    The use of second-generation antipsychotics (SGAs) for the treatment of schizophrenia has surged worldwide. Amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, sertindole and ziprasidone have now been commonly prescribed. Their effects on QT interval differ but evidence remains sparse and mostly inconclusive. Since prolongation of heart-rate corrected QT interval has been implicated as an useful surrogate marker to predict drug-related cardiac mortality and pro-arrhythmic potentials, it is timely and necessary to compare the effects of Bazett\u2019s corrected QT interval (QT\n                    <jats:sub>Bc<\/jats:sub>\n                    ) prolongation for the commonly prescribed SGAs. A meta-analysis was conducted according to suggestions by the Quality of Reporting of Meta-analysis group with literature identified using various databases and augmented with hand-searching to assess the magnitude and risk on QT\n                    <jats:sub>Bc<\/jats:sub>\n                    prolongation by these seven SGAs for treatments in adult subjects with schizophrenia. Because of incomplete QT\n                    <jats:sub>Bc<\/jats:sub>\n                    data reporting, quetiapine could not be assessed by the meta-analytical approach in this study. Aripiprazole was the only SGA associated with both statistically significant lower risk and mean change in QT\n                    <jats:sub>Bc<\/jats:sub>\n                    , with sertindole giving a statistically significant worsening effect on mean QT\n                    <jats:sub>Bc<\/jats:sub>\n                    . Other analyses did not demonstrate any statistically significant pooled effects for the studied SGAs, neither on the magnitude over mean or mean change, nor the risk on QT\n                    <jats:sub>Bc<\/jats:sub>\n                    prolongation.\n                  <\/jats:p>","DOI":"10.1177\/0269881110376685","type":"journal-article","created":{"date-parts":[[2010,9,8]],"date-time":"2010-09-08T21:15:08Z","timestamp":1283980508000},"page":"646-666","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":48,"title":["Effects on prolongation of Bazett\u2019s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis"],"prefix":"10.1177","volume":"25","author":[{"given":"Albert KK","family":"Chung","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Queen Mary Hospital, Hong Kong."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew-eng","family":"Chua","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Queen Mary Hospital, Hong Kong."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2010,9,8]]},"reference":[{"key":"bibr1-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200102000-00003"},{"key":"bibr2-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.83.6.1888"},{"key":"bibr3-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.70.1.43"},{"key":"bibr4-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.16.2120"},{"key":"bibr5-0269881110376685","volume-title":"Practice Guidelines for the Treatment of Patients with Schizophrenia","author":"American Psychiatric Association (APA)","year":"2004","edition":"2"},{"key":"bibr6-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1665.2002.00419.x"},{"key":"bibr7-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00190-X"},{"key":"bibr8-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1325"},{"key":"bibr9-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1097\/01.yic.0000177020.26311.a7"},{"key":"bibr10-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002083"},{"key":"bibr11-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245617"},{"key":"bibr12-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(95)00069-P"},{"key":"bibr13-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006617.pub2"},{"key":"bibr14-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199604000-00008"},{"key":"bibr15-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.171.6.502"},{"key":"bibr16-0269881110376685","doi-asserted-by":"crossref","first-page":"1S","DOI":"10.1177\/070674370505000101","volume":"50","author":"Canadian Psychiatric Association","year":"2005","journal-title":"Can J Psychiatry"},{"key":"bibr17-0269881110376685","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0104"},{"key":"bibr18-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1992.tb01473.x"},{"key":"bibr19-0269881110376685","volume-title":"Review Manager (RevMan) Version 5.0.20 [Computer program]","author":"Cochrane Collaboration","year":"2009"},{"key":"bibr20-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.5.765"},{"key":"bibr21-0269881110376685","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161140-00014"},{"key":"bibr22-0269881110376685","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4088\/JCP.v62n0310","volume":"62","author":"Czekalla J","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"bibr23-0269881110376685","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0310"},{"key":"bibr24-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001359.pub2"},{"key":"bibr25-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"bibr26-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004578.pub3"},{"key":"bibr27-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.189.2.102"},{"key":"bibr28-0269881110376685","unstructured":"Eli-Lilly Co. Ltd EUSPC31AUG05. Zyprexa product insert. 2005."},{"key":"bibr29-0269881110376685","volume-title":"The Assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal Products","author":"European Medicines Agency (EMEA) Committee for Proprietary Medicinal Products","year":"1997"},{"key":"bibr30-0269881110376685","volume-title":"The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs","author":"European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP)","year":"2005"},{"key":"bibr31-0269881110376685","volume-title":"The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Note for Guidance on the Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals","author":"European Medicines Agency (EMEA) Committee for Proprietary Medicinal Products (CPMP)","year":"2005"},{"key":"bibr32-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/0149-2918(95)80102-2"},{"key":"bibr33-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1097\/00132580-200205000-00009"},{"key":"bibr34-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1046\/j.1540-8167.2004.03534.x"},{"key":"bibr35-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2008.07.033"},{"key":"bibr36-0269881110376685","volume-title":"The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs","author":"Food and Drug Administration (FDA)","year":"2002"},{"key":"bibr37-0269881110376685","author":"Food and Drug Administration (FDA)","year":"2005","journal-title":"S7B Nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Guidance for Industry."},{"key":"bibr38-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002306"},{"key":"bibr39-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.11.1774"},{"key":"bibr40-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.08.010"},{"key":"bibr41-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.5.479"},{"key":"bibr42-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.01.040"},{"key":"bibr43-0269881110376685","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262110-00006"},{"key":"bibr44-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004410"},{"key":"bibr45-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000104913.75206.62"},{"key":"bibr46-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7372.1070"},{"key":"bibr47-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"bibr48-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/9780470712184"},{"key":"bibr49-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009933509868"},{"key":"bibr50-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000440"},{"key":"bibr51-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"bibr52-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005237.pub2"},{"key":"bibr53-0269881110376685","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0603"},{"key":"bibr54-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60486-9"},{"key":"bibr55-0269881110376685","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0903"},{"key":"bibr56-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1097\/01.yic.0000182114.65134.81"},{"key":"bibr57-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006569.pub3"},{"key":"bibr58-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02074-5"},{"key":"bibr59-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4002136"},{"key":"bibr60-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61764-X"},{"key":"bibr61-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08030368"},{"key":"bibr62-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001715.pub2"},{"key":"bibr63-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"bibr64-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145705005250"},{"key":"bibr65-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.6.696"},{"key":"bibr66-0269881110376685","unstructured":"Lundbeck Ltd Sertindole Monograph. 2006."},{"key":"bibr67-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2007.05.002"},{"key":"bibr68-0269881110376685","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.1993.34.2.179"},{"key":"bibr69-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)01085-X"},{"key":"bibr70-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04149-5"},{"key":"bibr71-0269881110376685","doi-asserted-by":"publisher","DOI":"10.3310\/hta3120"},{"key":"bibr72-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.9.943"},{"key":"bibr73-0269881110376685","volume-title":"Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia","author":"National Institute of Clinical Excellence (NICE)","year":"2002"},{"key":"bibr74-0269881110376685","volume-title":"NICE implementation update report: atypical antipsychotic drugs for the treatment of schizophrenia","author":"National Institute of Clinical Excellence (NICE)","year":"2008"},{"key":"bibr75-0269881110376685","volume-title":"Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). National clinical practice guideline number 82","author":"National Institute of Clinical Excellence (NICE)","year":"2009"},{"key":"bibr76-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.166.6.712"},{"key":"bibr77-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1997.tb10162.x"},{"key":"bibr78-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(99)00075-X"},{"key":"bibr79-0269881110376685","unstructured":"Pfizer Inc Zeldox Monograph. 2002."},{"key":"bibr80-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.7.681"},{"key":"bibr81-0269881110376685","first-page":"2137","volume":"360","author":"Price LH","year":"2009","journal-title":"N Engl J Med"},{"key":"bibr82-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022147"},{"key":"bibr83-0269881110376685","volume-title":"FDA Background on ZeldoxTM (Ziprasidone Hydrochloride capsules) Pfizer, Inc. Cardio Review","author":"Psychopharmacological Drugs Advisory Committee","year":"2000"},{"key":"bibr84-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.12.1161"},{"key":"bibr85-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806994"},{"key":"bibr86-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02035-3"},{"key":"bibr87-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032426"},{"key":"bibr88-0269881110376685","author":"Royal College of Psychiatrists","year":"2006","journal-title":"Consensus statement on high-dose antipsychotic medication. Council Report CR 138, 24"},{"key":"bibr89-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.02.017"},{"key":"bibr90-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.10.1123"},{"key":"bibr91-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1046\/j.1472-8206.2002.00083.x"},{"key":"bibr92-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.7.2.181"},{"key":"bibr93-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001357"},{"key":"bibr94-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830180067009"},{"key":"bibr95-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000967.pub2"},{"key":"bibr96-0269881110376685","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Becker BJ, Egger M The Funnel Plot. Publication Bias in Meta-analysis. Prevention, Assessment and Adjustments 2005 West Sussex: John Wiley & Sons Ltd, 75\u201398.","DOI":"10.1002\/0470870168.ch5"},{"key":"bibr97-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1097\/01.yic.0000166405.49473.70"},{"key":"bibr98-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.12.1293"},{"key":"bibr99-0269881110376685","doi-asserted-by":"publisher","DOI":"10.3109\/9780203092835"},{"key":"bibr100-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6965.1351"},{"key":"bibr101-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2004.03.016"},{"key":"bibr102-0269881110376685","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528010-00003"},{"key":"bibr103-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199710000-00010"},{"key":"bibr104-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000966"},{"key":"bibr105-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.09.010"},{"key":"bibr106-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1996.tb10653.x"},{"key":"bibr107-0269881110376685","first-page":"154","volume":"25","author":"Welch R","year":"2000","journal-title":"J Psychiatry Neurosci"},{"key":"bibr108-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200302000-00010"},{"key":"bibr109-0269881110376685","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.12.1168"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881110376685","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0269881110376685","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881110376685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:06:35Z","timestamp":1777507595000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881110376685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,8]]},"references-count":109,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1177\/0269881110376685"],"URL":"https:\/\/doi.org\/10.1177\/0269881110376685","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,8]]}}}